CannTrust announces new medical brand estora™
by CM Staff
CannTrust re-enters medical cannabis market.
VAUGHAN — CannTrust Holdings Inc. announces it is re-entering the Canadian medical cannabis market on Jan. 8 with its new medical brand estora™, and will begin serving patients immediately.
“Since our inception, we have been dedicated to providing Canadians with consistently high-quality medical cannabis,” said Greg Guyatt, Chief Executive Officer at CannTrust. “We’re delighted to be launching our new medical brand estora™ with a portfolio of medical cannabis products including oil drops, capsules and dried flower formats.”
“We believe it was imperative to evolve our strong foundation in medical cannabis to meet the changing needs of our patients,” said Guyatt. “estora™ has patient care at its core. We consulted patients and health care practitioners, learning more about their needs and refining our processes and product offerings to elevate their experience with us.”
CannTrust remains under CCAA protection to facilitate its efforts to resolve its civil litigation claims and complete its review of strategic alternatives. CannTrust’s re-entry into the medical cannabis industry is a move to rebuild trust following a 2019 inspection uncovering that it grew thousands of kilograms of marijuana in unlicensed rooms.
